Dengue Vaccine Market (2025 - 2033)

Dengue Vaccine Market Summary

The global dengue vaccine market size was estimated at USD 423.18 million in 2024 and is projected to reach USD 1,618.61 million by 2033, growing at a CAGR of 13.73% from 2025 to 2033. The increasing prevalence of dengue fever across tropical and subtropical regions drives strong demand for effective vaccines.

The increasing urbanization and population density create favorable conditions for Aedes mosquitoes, the primary carriers of the virus. The increasing frequency of outbreaks highlights urgent preventive needs, as seen in April 2025, when the World Stock Market reported Brazil had registered 1,010,833 probable cases, 668 confirmed deaths, and 724 under investigation, with São Paulo leading at 585,902 cases. The incidence rate was 475.5 per 100,000, lower than 1,881 per 100,000 in 2024. The increasing awareness among healthcare providers and patients, combined with advances in research, greater accessibility in clinics, and stronger pharmaceutical collaborations, accelerates vaccine adoption and supports global dengue control efforts.

In July 2025, KFF Health News reported a sharp rise in dengue cases across the contiguous United States. The number of new infections reached approximately 3,700, nearly doubling from about 2,050 cases in 2023. Of these, 105 cases were confirmed to be locally transmitted in California, Florida, and Texas, signaling a concerning trend in domestic spread. Historically, dengue infections in the U.S. were mostly travel-related, but the rising local transmission indicates that the Aedes aegypti mosquito has expanded its presence. This surge reflects changing environmental conditions and highlights growing risks for communities that previously faced minimal exposure to dengue. The sudden escalation of cases underscores an urgent need for preventive strategies, including vaccination, mosquito control, and improved monitoring.

The same report emphasized that environmental changes are increasing the risk of dengue outbreaks in U.S. regions. Rising global temperatures, longer rainy seasons, and expanding mosquito breeding sites have created favorable conditions for Aedes aegypti, the main dengue carrier. Warmer climates extend mosquito survival and allow the virus to circulate for longer periods, leading to higher infection rates. With 3,700 total cases in 2024, compared to 2,050 cases in 2023, the doubling of infections shows how these factors are affecting the situation. Local transmission in 105 cases across California, Florida, and Texas demonstrates how climate change and urban density intersect to speed up disease spread. These trends highlight the need to strengthen vaccination campaigns, improve public awareness, and expand community efforts to reduce the rising burden of dengue in the U.S.

Pipeline Analysis

Brazil has reported a high number of dengue cases, particularly in the Amazon region, due to environmental factors and inadequate infrastructure. The country's healthcare system faces challenges in providing equitable access to dengue prevention and treatment. Vaccination campaigns target high-risk populations to curb the spread of the disease. International aid and partnerships support Brazil's efforts in combating dengue. Research initiatives focus on developing effective vaccines and improving vector control methods. Brazil's comprehensive approach aims to reduce the burden of dengue and protect public health.

Middle East & Africa Dengue Vaccine Market Trends

The Middle East & Africa region has reported sporadic cases of dengue, primarily in travelers returning from endemic areas. The region's healthcare infrastructure varies, influencing the capacity to respond to dengue threats. Public health initiatives focus on raising awareness about dengue risks and preventive measures. Collaborations with international organizations support research and development efforts. Vector control programs aim to reduce mosquito populations and prevent transmission. The region's proactive stance aims to mitigate the impact of dengue and protect public health.

Saudi Arabia has reported isolated cases of dengue, often linked to travel, highlighting the need for preventive measures. The country's healthcare system provides guidance on dengue prevention, including vaccination recommendations for travelers. Public health campaigns educate citizens about the risks of dengue and the importance of preventive measures. Saudi Arabia's participation in regional health initiatives supports global efforts to combat dengue. Research collaborations focus on developing effective vaccines and vector control methods. Saudi Arabia's integrated approach aims to safeguard its population from dengue.

Key Dengue Vaccine Company Insights

Sanofi plays a pivotal role in the dengue vaccine market with its early introduction of Dengvaxia, which provided the first licensed option for dengue prevention and established the company’s strong presence in endemic countries. Its wide distribution networks and clinical expertise strengthened its leadership in this field. Takeda Pharmaceutical Company Limited drives growth through Qdenga (TAK-003), a tetravalent vaccine delivering broad protection against all four dengue serotypes. With expanding approvals across Asia, Europe, and Latin America, Takeda continues to scale global access. Together, both companies shape the competitive landscape through innovation, clinical development, and strategic geographic expansion.

Recent Developments

• In June 2025, Merck (MSD) launched the Phase III MOBILIZE-1 trial for its live attenuated quadrivalent dengue vaccine, V181. The study assessed prevention of symptomatic dengue, severe cases, warning signs, and hospitalization across all four virus serotypes, addressing a global public health threat.

• In May 2025, Takeda planned to launch its dengue vaccine, Qdenga, in India by 2026. Partnering with Biological E, the company aimed to produce 50 million doses annually. The tetravalent two-dose vaccine had already been approved in 40 countries.

• In October 2023, Takeda announced that the WHO’s SAGE recommended its dengue vaccine, QDENGA, for children aged 6-16 in high-burden areas. The two-dose vaccine, given three months apart, was evaluated across 19 trials involving over 28,000 participants, with emphasis on community engagement and strategic communication.

Dengue Vaccine Market